TUCSON, Ariz. – The Arizona Cancer Center is recruiting for a smoking-cessation vaccine research study up to 50 people, ages 18 to 65, who smoke and are ready to quit.
Arizona Cancer Center researcher Scott Leischow, PhD, is the local lead for a nationwide clinical trial for an investigational vaccine to treat nicotine addiction and help prevent smoking relapse.
“Smoking cessation is often the most difficult experience in the life of a smoker,” Dr. Leischow said. “This study will explore a novel approach, a nicotine vaccine, to help more smokers quit.”
The study is being funded in part by a $10 million grant from the U.S. National Institute on Drug Abuse, part of the National Institutes of Health.
The investigational vaccine, NicVAX® (Nicotine Conjugate Vaccine), is manufactured by Nabi Biopharmaceuticals of Rockville, Md. This Phase III double-blind, placebo-controlled research study will enroll approximately 1,000 participants.
For more information on this research study or to find out if you are qualified, call (520) 626-1900.
The Arizona Cancer Center is the only National Cancer Institute-designated comprehensive cancer center headquartered in Arizona. With primary locations at the University of Arizona in Tucson and in Scottsdale, the Center has more than a dozen research and education offices throughout the state and 300 physician and scientist members working to prevent and cure cancer. For more information, go to www.arizonacancercenter.org